Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3696]

An errant editing enzyme promotes tumour suppressor loss and leukaemia propagation

An errant editing enzyme promotes tumour suppressor loss and leukaemia propagation

Cancer cells steer a jagged path

Cancer cells steer a jagged path

Breast cancer drugs could help treat resistant lung cancers

Breast cancer drugs could help treat resistant lung cancers

Olaparib approved by FDA for first-line maintenance therapy in BRCA-mutated advanced ovarian cancer

Olaparib approved by FDA for first-line maintenance therapy in BRCA-mutated advanced ovarian cancer

Scientists advise caution in immunotherapy research

Scientists advise caution in immunotherapy research

ASH 2018: Daratumumab increases progression-free survival in transplant-ineligible multiple myeloma

ASH 2018: Daratumumab increases progression-free survival in transplant-ineligible multiple myeloma

ASH 2018: A first stem cell transplant after CAR T-Cell therapy reduces relapses in ALL

ASH 2018: A first stem cell transplant after CAR T-Cell therapy reduces relapses in ALL

$ASH 2018: Longer term data validate durable responses with tisagenlecleucel in adults with relapsed and refractory DLBCL$

ASH 2018: Longer term data validate durable responses with tisagenlecleucel in adults with relapsed and refractory...

ASH 2018: Tisagenlecleucel continues to show durable remissions in kids and young adults with stubborn form of leukaemia

ASH 2018: Tisagenlecleucel continues to show durable remissions in kids and young adults with stubborn form of...

ASH 2018: CAR T-Cell therapies show durable responses, new research also explores combination therapies to extend and enhance treatment responses

ASH 2018: CAR T-Cell therapies show durable responses, new research also explores combination therapies to extend...

More from ecancer